Literature DB >> 17495309

Direct and indirect costs of rabies exposure: a retrospective study in southern California (1998-2002).

Stephanie A Shwiff1, Ray T Sterner, Michele T Jay, Shefali Parikh, Amy Bellomy, Martin I Meltzer, Charles E Rupprecht, Dennis Slate.   

Abstract

The direct and indirect costs of suspected human rabies exposure were estimated for San Luis Obispo and Santa Barbara counties, California, USA. Clinic, hospital, and county public health records (1998-2002) were examined to determine direct costs for postexposure prophylaxis (PEP), and 55 (41%) former patients were contacted to voluntarily provide estimates of their indirect costs associated with receiving PEP. Additional costs due to public health and animal control personnel responses to rabid animals were collected, including diagnostic testing and wages. The mean total cost of a suspected human rabies exposure was $3,688, the direct costs per case were $2,564, and the indirect costs were $1,124 of that total. About one third of the total cost for suspected human rabies exposure was attributed to indirect costs (e.g., lost wages, transportation, and day-care fees), most of which were not reimbursable to the patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495309     DOI: 10.7589/0090-3558-43.2.251

Source DB:  PubMed          Journal:  J Wildl Dis        ISSN: 0090-3558            Impact factor:   1.535


  14 in total

1.  Rabies prevention and management of cats in the context of trap-neuter-vaccinate-release programmes.

Authors:  A D Roebling; D Johnson; J D Blanton; M Levin; D Slate; G Fenwick; C E Rupprecht
Journal:  Zoonoses Public Health       Date:  2013-07-17       Impact factor: 2.702

2.  Characterization of Emergency Department Rabies Post-Exposure Prophylaxis Procedures with an Infectious Diseases Clinic Referral Process.

Authors:  Jessica J Frederickson; Alexandra K Monroe; Gregory A Hall; Kyle A Weant
Journal:  Hosp Pharm       Date:  2020-11-24

3.  Estimating the risk of rabies transmission to humans in the U.S.: a Delphi analysis.

Authors:  Sagar A Vaidya; Susan E Manning; Praveen Dhankhar; Martin I Meltzer; Charles Rupprecht; Harry F Hull; Daniel B Fishbein
Journal:  BMC Public Health       Date:  2010-05-26       Impact factor: 3.295

4.  Use of rabies postexposure prophylaxis supplied by the Alaska Section of Epidemiology, Alaska, 2002-2007.

Authors:  Louisa Castrodale
Journal:  Public Health Rep       Date:  2009 Mar-Apr       Impact factor: 2.792

5.  Graphically characterizing the movement of a rabid striped skunk epizootic across the landscape in northwestern Wyoming.

Authors:  Craig A Ramey; Kenneth W Mills; Justin W Fischer; Robert G McLean; Kathleen A Fagerstone; Richard M Engeman
Journal:  Ecohealth       Date:  2013-06-29       Impact factor: 3.184

6.  Rabies surveillance in the United States during 2011.

Authors:  Jesse D Blanton; Jessie Dyer; Jesse McBrayer; Charles E Rupprecht
Journal:  J Am Vet Med Assoc       Date:  2012-09-15       Impact factor: 1.936

7.  Exposure of US travelers to rabid zebra, Kenya, 2011.

Authors:  Emily W Lankau; Joel M Montgomery; Danielle M Tack; Mark Obonyo; Samuel Kadivane; Jesse D Blanton; Wences Arvelo; Emily S Jentes; Nicole J Cohen; Gary W Brunette; Nina Marano; Charles E Rupprecht
Journal:  Emerg Infect Dis       Date:  2012-07       Impact factor: 6.883

8.  A one health framework for the evaluation of rabies control programmes: a case study from Colombo City, Sri Lanka.

Authors:  Barbara Häsler; Elly Hiby; Will Gilbert; Nalinika Obeyesekere; Houda Bennani; Jonathan Rushton
Journal:  PLoS Negl Trop Dis       Date:  2014-10-23

Review 9.  Tactics and economics of wildlife oral rabies vaccination, Canada and the United States.

Authors:  Ray T Sterner; Martin I Meltzer; Stephanie A Shwiff; Dennis Slate
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

Review 10.  Potential economic benefits of eliminating canine rabies.

Authors:  Stephanie Shwiff; Katie Hampson; Aaron Anderson
Journal:  Antiviral Res       Date:  2013-03-13       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.